Actualización del abordaje farmacológico de la enfermedad Esteatósica Asociada a Disfunción Metabólica
DOI:
https://doi.org/10.55204/scc.v2i2.e33Palabras clave:
drogas en investigación, epidemiología, enfermedad del hígado graso no alcohólico, resultado del tratamiento, terapéuticaResumen
Introducción: la enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD) es una afección con alta prevalencia y morbimortalidad, considerada como un problema de salud pública, que no solo afecta a la salud individual y economía familiar, sino que ha ocasionado un gran impacto en los costos de sistemas de atención médica a nivel global.
Objetivo: describir la actualización del abordaje farmacológico de la enfermedad esteatósica asociada a disfunción metabólica
Resultados: la MASLD está estrechamente vinculada a enfermedades cardiovasculares, lo que resalta la importancia de enfoques holísticos y estrategias de prevención adaptadas a diferentes poblaciones. Además, se está avanzando en el tratamiento de MASLD, explorando medicamentos hipoglucemiantes y agentes como GLP-1 para reducir la acumulación de grasa hepática.
Conclusiones: La MASLD está estrechamente relacionada con las ECV, representando un riesgo independiente. Su creciente prevalencia exige un enfoque holístico que incluye concienciación, detección temprana, estratificación de riesgos, tratamiento multidisciplinario y colaboración en investigación.
Descargas
Citas
Leow W, Chan A, Mendoza P. Non-alcoholic fatty liver disease: the pathologist’s perspective. Clin Mol Hepatol. 2023;29(6):302–18.
Kang S, Lee H, Yoo J. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(3):363–401.
Jung H, Chang Y, Kwon M. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J Gastroenterol. 2019;114(3):453–63.
Kim G, Lee S, Lee Y. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. Hepatology. 2018;68(5):1755–68.
Li J, Zou B, Yeo Y. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–98.
Jang H, Kang D, Sinn D. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: A cohort study. Sci Rep. 2018;8(1):6–12.
Younossi Z. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019;70(3):531–44.
Eguchi Y, Wong G, Lee E. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open. 2020;4(5):808–17.
Quek J, Chan K, Wong Z. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30.
Bullón M, Abete I, Zulet M. Risk factors differentially associated with non-alcoholic fatty liver disease in males and females with metabolic syndrome. Rev Española Enfermedades Dig. 2019;112(2):94–100.
Bernal R, Icaza M, Chi L. Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: An open population study. Rev Gastroenterol Mex. 2022;2(5):19–22.
Huang D, Serag H, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–8.
Kanwal F, Kramer J, Li L. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71(3):808–19.
Ascha M, Hanouneh I, Lopez R. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972–8.
Lee Y ho, Cho Y, Lee B. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43(1):31–45.
Aguilera A. Nonalcoholic hepatic steatosis: a silent disease. Rev Med Inst Mex Seguro Soc. 2019;56(6):544–9.
Frediani J, Naioti E, Vos M. Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014. Environ Health. 2018;17(1):56–62.
Kim T, Sinn D, Min Y. A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. J Gastroenterol. 2017;52(11):1201–10.
Lee S, Park G, Lee J. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. J Hepatol. 2018;68(5):1018–24.
Bellentani S, Scaglioni F, Marino M. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2018;28(1):155–61.
Campo J, Gallego R, Gallego P. Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). Int J Mol Sci. 2018;19(3):911–9.
Zhao L, Zhang X, Coday M. Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality. JAMA. 2023;330(6):537–46.
Basaranoglu M, Neuschwander B. Nonalcoholic fatty liver disease: Clinical features and pathogenesis. Gastroenterol Hepatol. 2006;2(4):282–91.
Brunt E, Tiniakos D. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16(42):5286–96.
Kudaravalli P, John S. Nonalcoholic Fatty Liver. StatPearls. 2023. 1–15 p.
Yin X, Guo X, Liu Z. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2023;24(3):69–72.
Saokaew S, Kanchanasuwan S, Apisarnthanarak P. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). Liver Int. 2017;37(10):1535–43.
Bisaccia G, Ricci F, Khanji M, et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):16-22.
Chew N, Nag C, Muthiah M, et al. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep. 2022;24(7):515–32.
Arab J, Díaz L, Dirchwolf M, et al. NAFLD: Challenges and opportunities to address the public health challenge in Latin America. Ann Hepatol. 2021;24(9):100-9.
Byrne C, Targher G. Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people? Gut. 2023;72(7):1238–9.
Byrne C, Targher G. Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. Gut. septiembre de 2022;71(9):1695–6.
Targher G, Tilg H, Byrne C. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–88.
Kongmalai T, Srinonprasert V, Anothaisintawee T, Kongmalai P, McKay G, Attia J, et al. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol. 2023;14(6):1–12.
Zhu Y, Tan J, Wong S, et al. Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023;24(11):56-61.
Yuan X, Gao Z, Yang C, et al. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis. Front Endocrinol. 2023;14(6):1–12.
Liu A, Cai Y, Yuan Y, et al. Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis. Syst Rev. 2023;12(1):1–12.
Ferguson D, Finck B. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17(8):484–95.
Kamata S, Honda A, Ishii I. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Biomolecules. 2023;13(8):62-8.
Majzoub A, Nayfeh T, Barnard A, et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021;54(7):880–9.
Chin K, Prieto M, Cheong C, et al. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature. Hpb. 2021;23(8):1164–74.
Kovalic A, Gozar M, Da B, et al. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. el 17 de enero de 2023;35(1):102–11.
Pennisi G, Celsa C, Enea M, et al. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis. Nutr Metab Cardiovasc Dis. 2022;32(10):2279–88.
Jin Z, Yuan Y, Zheng C, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. agosto de 2023;37(8):108558.
Zhou H, Toshiyoshi, M, Zhao W, et al. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). el 30 de junio de 2023;102(26):e33981.
Zhou X, Wang J, Zhou S, et al. Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. Med (United States). 2023;102(4):E32734.
Naghipour A, Amini E, Orang M, et al. Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. Syst Rev. 2023;12(1):1–19.
Lukkunaprasit T, Tansawet A, Boonmanunt S, et al. An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand. Sci Rep. 2023;13(1):1–13.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Xavier Oswaldo Jara Ramón, Paola Verónica Orellana Bernal
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores conservan los derechos morales y patrimoniales de sus obras. Puesto que Salud ConCiencia es una publicación de acceso abierto, los lectores pueden reproducir total o parcialmente su contenido siempre y cuando proporcionen adecuadamente el crédito a los autores correspondientes y a la revista misma.
Nuestra revista se rige por las políticas internacionales SHERPA/RoMEO: Revista verde: Permiten el autoarchivo tanto del pre-print (borrador de un trabajo) como del post-print (la versión corregida y revisada por pares) y hasta de la versión final (maquetada tal como saldrá publicada en la revista).
Véase también "Derechos de autor y licencias".
